Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11926-020-00964-x http://scihub22266oqcxt.onion/10.1007/s11926-020-00964-x 33044642!7549425!33044642     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Rheumatol+Rep 2020 ; 22 (12): 84 Nephropedia Template TP {{tp|p=33044642|t=2020. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future |pdf=|usr=}}{{33044642}} gab.com Text Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future JO: Curr Rheumatol Rep http://www.kidney.de/pget.php?&tw=1&pmid=33044642 #FOAvip PURPOSE OF REVIEW: Guidelines for the management of large vessel vasculitides have been recently updated by several scientific societies. We have evaluated the current recommendations for treatment of giant cell arteritis (GCA) and Takayasu arteritis (TA) and addressed potential future therapeutic strategies. RECENT FINDINGS: While glucocorticoids (GCs) remain the gold standard for induction of remission, many patients relapse and acquire high cumulative GC exposure. Thus, GC-sparing therapies such as methotrexate are recommended for selected patients with GCA and all patients with TA. Recent high-quality evidence shows that tocilizumab is an effective GC-sparing agent in GCA. Non-biologic and biologic immunomodulators also appear to have GC-sparing properties in TA. Tocilizumab is now considered to be part of the standard treatment for GCA, particularly with relapsing disease, but questions on its use such as length of treatment and monitoring of disease activity remain open. High-quality evidence to guide treatment of TA is still lacking. Twit Text FOAVip Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future ????Curr Rheumatol Rep http://www.kidney.de/pget.php?&tw=1&pmid=33044642 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33044642 #FOAvip English Wikipedia <ref>{{Cite pmid|33044642}}</ref> Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future #MMPMID33044642 Hellmich B; Agueda AF; Monti S; Luqmani R Curr Rheumatol Rep 2020[Oct]; 22 (12): 84 PMID33044642show ga PURPOSE OF REVIEW: Guidelines for the management of large vessel vasculitides have been recently updated by several scientific societies. We have evaluated the current recommendations for treatment of giant cell arteritis (GCA) and Takayasu arteritis (TA) and addressed potential future therapeutic strategies. RECENT FINDINGS: While glucocorticoids (GCs) remain the gold standard for induction of remission, many patients relapse and acquire high cumulative GC exposure. Thus, GC-sparing therapies such as methotrexate are recommended for selected patients with GCA and all patients with TA. Recent high-quality evidence shows that tocilizumab is an effective GC-sparing agent in GCA. Non-biologic and biologic immunomodulators also appear to have GC-sparing properties in TA. Tocilizumab is now considered to be part of the standard treatment for GCA, particularly with relapsing disease, but questions on its use such as length of treatment and monitoring of disease activity remain open. High-quality evidence to guide treatment of TA is still lacking. |*Giant Cell Arteritis/drug therapy[MESH] |*Takayasu Arteritis/drug therapy[MESH] |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |Glucocorticoids/therapeutic use[MESH] |Humans[MESH] |Methotrexate/therapeutic use[MESH]Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and F(epmc).pdf DeepDyve Pubget Overpricing